NASDAQ:QDELQuidel Stock Price, Forecast & News

$246.64

+1.68 (+0.69 %)

(As of 07/10/2020 04:00 PM ET)

Add

Compare

Today's Range

$242.02

Now: $246.64▼

$247.22

50-Day Range

$153.64

MA: $192.21▼

$244.96

52-Week Range

$52.49

Now: $246.64▼

$248.00

Volume522,900 shs

Average Volume1.69 million shs

Market Capitalization$10.36 billion

P/E Ratio120.31

Dividend YieldN/A

Beta1.16

Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology. The company offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye. It also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the determination of the presence of drug and/or the major metabolites in urine. In addition, the company offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates. Further, it provides biomarkers, which include clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation; and enzyme linked immunosorbent assays and reagents for the detection of activation products. Additionally, the company offers AmpliVue hand-held molecular diagnostic assay platform for the detection of the pathogen; Solana, an amplification and detection system; and Lyra molecular real-time polymerase chain reaction assays. The company markets its products through distributors and direct sales force for use in physician offices, hospitals, clinical laboratories, reference laboratories, leading universities, retail clinics, pharmacies, and wellness screening centers. Quidel Corporation was founded in 1979 and is headquartered in San Diego, California.

Beat the Market (BTM) Rank^™

1.2 Analyst's Opinion

Consensus Rating
Quidel has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 3 buy ratings, 2 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $161.83, Quidel has a potential downside of 34.4% from its current price of $246.64.
Amount of Analyst Coverage
Quidel has only been the subject of 3 research reports in the past 90 days.

2.6 Community Rank

Outperform Votes
Quidel has received 396 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Quidel has received 354 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Quidel has received 52.80% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Quidel and other stocks. Vote “Outperform” if you believe QDEL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe QDEL will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Quidel does not currently pay a dividend.
Dividend Growth
Quidel does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Quidel insiders have sold 3,169.68% more of their company's stock than they have bought. Specifically, they have bought $801,650.00 in company stock and sold $26,211,364.00 in company stock.
Percentage Held by Insiders
Only 14.10% of the stock of Quidel is held by insiders.
Percentage Held by Institutions
86.98% of the stock of Quidel is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Quidel are expected to grow by 14.62% in the coming year, from $7.25 to $8.31 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Quidel is 120.31, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 16.16.
Price to Earnings Ratio vs. Sector
The P/E ratio of Quidel is 120.31, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 25.68.
Price to Book Value per Share Ratio
Quidel has a P/B Ratio of 18.35. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.08 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Diagnostic substances

Sub-IndustryHealth Care Supplies

SectorMedical

Current SymbolNASDAQ:QDEL

Previous Symbol

CUSIP74838J10

CIK353569

Webwww.quidel.com

Phone858-552-1100

Debt

Debt-to-Equity Ratio0.15

Current Ratio2.10

Quick Ratio1.67

Price-To-Earnings

Trailing P/E Ratio120.31

Forward P/E Ratio34.02

P/E GrowthN/A

Sales & Book Value

Annual Sales$534.89 million

Price / Sales19.37

Cash Flow$4.30 per share

Price / Cash Flow57.40

Book Value$13.44 per share

Price / Book18.35

Profitability

EPS (Most Recent Fiscal Year)$2.73

Net Income$72.92 million

Net Margins15.73%

Return on Equity23.69%

Return on Assets14.58%

Miscellaneous

Employees1,250

Outstanding Shares42,000,000

Market Cap$10.36 billion

Next Earnings Date8/13/2020 (Estimated)

OptionableOptionable

Receive QDEL News and Ratings via Email

Sign-up to receive the latest news and ratings for QDEL and its competitors with MarketBeat's FREE daily newsletter.

Quidel (NASDAQ:QDEL) Frequently Asked Questions

How has Quidel's stock been impacted by COVID-19 (Coronavirus)?

Quidel's stock was trading at $89.68 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, QDEL stock has increased by 175.0% and is now trading at $246.64. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Quidel?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quidel in the last year. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Quidel.

When is Quidel's next earnings date?

Quidel is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Quidel.

How were Quidel's earnings last quarter?

Quidel Co. (NASDAQ:QDEL) posted its earnings results on Wednesday, May, 6th. The company reported $1.15 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.99 by $0.16. The company had revenue of $174.65 million for the quarter, compared to analysts' expectations of $157.12 million. Quidel had a return on equity of 23.69% and a net margin of 15.73%. View Quidel's earnings history.

What guidance has Quidel issued on next quarter's earnings?

Quidel updated its second quarter 2020 After-Hours earnings guidance on Monday, July, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $201-202 million, compared to the consensus revenue estimate of $178.91 million.

What price target have analysts set for QDEL?

6 brokerages have issued 1 year target prices for Quidel's stock. Their forecasts range from $75.00 to $306.00. On average, they anticipate Quidel's stock price to reach $161.83 in the next twelve months. This suggests that the stock has a possible downside of 34.4%. View analysts' price targets for Quidel.

Has Quidel been receiving favorable news coverage?

News coverage about QDEL stock has been trending extremely negative recently, InfoTrie Sentiment reports. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Quidel earned a media sentiment score of -4.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news about Quidel.

Are investors shorting Quidel?

Quidel saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 2,100,000 shares, an increase of 18.6% from the June 15th total of 1,770,000 shares. Based on an average daily volume of 1,120,000 shares, the short-interest ratio is presently 1.9 days. Approximately 5.7% of the shares of the stock are short sold. View Quidel's Current Options Chain.

Who are some of Quidel's key competitors?

Some companies that are related to Quidel include Align Technology (ALGN), West Pharmaceutical Services (WST), Cooper Companies (COO), DENTSPLY SIRONA (XRAY), Haemonetics (HAE), Neogen (NEOG), ICU Medical (ICUI), STAAR Surgical (STAA), Merit Medical Systems (MMSI), Atrion (ATRI), Cerus (CERS), Meridian Bioscience (VIVO), OraSure Technologies (OSUR), Anika Therapeutics (ANIK) and Antares Pharma (ATRS). View all competitors.

What other stocks do shareholders of Quidel own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Quidel investors own include NVIDIA (NVDA), Shopify (SHOP), Netflix (NFLX), Teladoc Health (TDOC), Trade Desk (TTD), Alibaba Group (BABA), Gilead Sciences (GILD), Twilio (TWLO), Adobe (ADBE) and Okta (OKTA).

Who are Quidel's key executives?

Quidel's management team includes the following people:

Mr. Douglas C. Bryant, Pres, CEO & Director (Age 61)
Mr. Randall J. Steward, Chief Financial Officer (Age 65)
Mr. Robert J. Bujarski, Sr. VP of Bus. Devel. & Gen. Counsel (Age 51)
Dr. Werner Kroll, Sr. VP of R&D (Age 62)
Mr. Edward Keith Russell, Sr. VP of Global Commercial Operations (Age 51)

What is Quidel's stock symbol?

Quidel trades on the NASDAQ under the ticker symbol "QDEL."

Who are Quidel's major shareholders?

Quidel's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Envestnet Asset Management Inc. (0.01%), Paragon Advisors LLC (0.01%), Symphony Financial Ltd. Co. (0.01%) and Private Trust Co. NA (0.00%). Company insiders that own Quidel stock include Charles P Slacik, Douglas C Bryant, Edward Keith Russell, Karen Gibson, Kenneth F Buechler, Mary Lake Ph D Polan, Michael Donald Jr Abney, Randall J Steward, Ratan S Borkar, Robert Joseph Bujarski, Thomas D Brown and Werner Kroll. View institutional ownership trends for Quidel.

Which major investors are buying Quidel stock?

QDEL stock was bought by a variety of institutional investors in the last quarter, including Paragon Advisors LLC, Symphony Financial Ltd. Co., Private Trust Co. NA, and Envestnet Asset Management Inc.. View insider buying and selling activity for Quidel.

How do I buy shares of Quidel?

Shares of QDEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Quidel's stock price today?

One share of QDEL stock can currently be purchased for approximately $246.64.

How big of a company is Quidel?

Quidel has a market capitalization of $10.36 billion and generates $534.89 million in revenue each year. The company earns $72.92 million in net income (profit) each year or $2.73 on an earnings per share basis. Quidel employs 1,250 workers across the globe.

What is Quidel's official website?

The official website for Quidel is www.quidel.com.

How can I contact Quidel?

Quidel's mailing address is 9975 SUMMERS RIDGE ROAD, SAN DIEGO CA, 92121. The company can be reached via phone at 858-552-1100 or via email at [email protected]

This page was last updated on 7/12/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings